Isa Iber VD

Phase 1b/2: Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myelomant

What's the purpose of the trial?

This study is to evaluate the combination of isatuximab, iberdomide, bortezomib, and dexamethasone in newly diagnosed multiple myeloma participants who are transplant ineligible or not intended for upfront transplant. The names of the study drugs used in this research study are: isatuximab, iberdomide, bortezomib dexamethasone

Trial status

Not yet accepting

Phase

Phase 1/2

Enrollment

Last Updated

Participating Centers

There are 2 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

Dexamethasone
Isatuximab
Iberdomide
Bortezomib

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Not yet accepting

Arm A: <70 and Fit (Standard-intensity Schedule)

Not yet accepting

Arm B: Age ≥70 and/or Intermediate Fit/Frail (Reduced-intensity Schedule)

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.